Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Overview of attention for article published in Breast Cancer Research, December 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 3 patents

Citations

dimensions_citation: 54 Dimensions

Readers on

mendeley: 60 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

P13K INHIBITOR COMBINATION THERAPY

Application WO-2024023766-A1

World Intellectual Property Organisation (WIPO)

METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN…

Application WO-2022132652-A1

World Intellectual Property Organisation (WIPO)

METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS

Application WO-2020118213-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.